Qiagen (NYSE:QGEN) Announces Earnings Results

Qiagen (NYSE:QGEN) released its quarterly earnings data on Wednesday. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.01, Zacks reports. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The firm had revenue of $540.42 million for the quarter, compared to the consensus estimate of $528.53 million. During the same quarter in the prior year, the company posted $0.61 earnings per share. The business’s revenue was up 3.6% on a year-over-year basis. Qiagen updated its FY 2026 guidance to 2.500- EPS and its Q1 2026 guidance to 0.540- EPS.

Qiagen Stock Down 0.2%

QGEN opened at $51.79 on Thursday. Qiagen has a twelve month low of $39.61 and a twelve month high of $57.81. The company’s 50-day moving average price is $49.62 and its two-hundred day moving average price is $49.66. The stock has a market cap of $10.94 billion, a price-to-earnings ratio of 26.74, a PEG ratio of 2.49 and a beta of 0.67. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45.

Hedge Funds Weigh In On Qiagen

Institutional investors have recently bought and sold shares of the company. Danske Bank A S purchased a new stake in Qiagen in the third quarter worth $36,000. Advisory Services Network LLC bought a new position in shares of Qiagen during the 3rd quarter worth $64,000. EverSource Wealth Advisors LLC increased its holdings in Qiagen by 226.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after acquiring an additional 1,802 shares during the last quarter. Osaic Holdings Inc. increased its holdings in Qiagen by 101.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after acquiring an additional 1,951 shares during the last quarter. Finally, Pitcairn Co. bought a new stake in Qiagen in the 2nd quarter valued at about $208,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

More Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Q4 results: EPS of $0.62 and revenue growth of ~3.6% YoY; the company showed solid margins (net margin ~19.6%) and return on equity (~14.8%), which support the earnings quality. View Press Release
• Positive Sentiment: Product/market expansion: Qiagen showcased QIAsprint Connect — a benchtop high-throughput automation system — at SLAS 2026, signaling entry into higher-volume sample‑processing for research labs (potential long‑term revenue upside). Article Title
• Positive Sentiment: Analyst sentiment: Several media/analyst write‑ups highlighted Qiagen among favored healthcare names, which can provide continued analyst support for the shares. Article Title
• Neutral Sentiment: Street comparisons: Coverage summarizes how key Q4 metrics stack up to Wall Street — results are largely in line with expectations but show only modest year‑over‑year improvement. Article Title
• Negative Sentiment: Guidance miss: Management lowered near‑term expectations — Q1 EPS guidance of ~$0.54 (consensus ~$0.60) and Q1 revenue guidance of ~$487.8M (consensus ~$511.8M); FY‑2026 EPS guide of ~$2.50 vs. consensus ~$2.63, while FY revenue guidance is roughly in line. The below‑consensus EPS and Q1 revenue outlook are the primary reasons the stock is under pressure. View Press Release

Analysts Set New Price Targets

A number of brokerages have commented on QGEN. UBS Group reissued a “neutral” rating on shares of Qiagen in a report on Wednesday, January 21st. Barclays reiterated an “overweight” rating and set a $57.89 price target (up previously from $55.79) on shares of Qiagen in a report on Monday, December 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft downgraded shares of Qiagen from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $52.00 to $54.00 in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Two analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $53.04.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.